As chief medical officer of Moderna, Tal Zaks used to be skeptical of genome editing.
Why repair a patient’s broken gene, he would ask, with all the havoc CRISPR can wreak on DNA, when a company like Moderna can just replace that gene with regular, transient doses of mRNA? (One reason: Moderna was having immense difficulty doing just that.)
On Tuesday, though, Zaks emerged after years outside the spotlight as, of all things, acting CEO of a new genome editing company. Called Exsilio Therapeutics, the startup emerged from stealth with $82 million in Series A funding and a seed round led by OrbiMed, where Zaks has been a partner since shortly after he left Moderna in 2021.
Click this link for the original source of this article.
Author: Jason Mast
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.